Defining the maximum tolerated dose: Investigator, academic, industry and regulatory perspectives

Journal of Clinical Pharmacology

Volumn 37, Issue 9, 1997, Pages 767-783

  Cutler, Neal R ^a,g   Sramek, John J ^a   Greenblatt, David J ^b   Chaikin, Philip ^c   Ford, Neville ^d   Lesko, Lawrence J ^e   Davis, Brian ^f   Williams, Roger L ^e  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Worldwide Clinical Development   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CL 254846; CYTOCHROME P450; HEPTYLSTIGMINE TARTRATE; HYPNOTIC AGENT; MACROGOL 400; RIVASTIGMINE; TRIAZOLAM; UNCLASSIFIED DRUG;

ATAXIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSYCHOMOTOR PERFORMANCE; RISK ASSESSMENT; TACHYCARDIA; VOMITING;

EID: 0030763644     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb05624.x     Document Type: Conference Paper

References (35)

1. Cutler NR, Sramek JJ, Veroff AE: Alzheimer's Disease: Optimizing Drug Development Strategies. Chichester: John Wiley & Sons, 1994.
2. Cutler NR, Sramek JJ, Kurtz NM: Anxiolytic Compounds: Perspectives in Drug Development. Chichester: John Wiley & Sons, 1996.
3. Cutler NR, Sramek JJ: Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995b;48:421-428.
4. Koch HJ: Concept of bridging studies and ethical concerns. Eur J Pharmacol 1996;50:245-246.
5. Carter SK: Clinical trials in cancer chemotherapy. Cancer 1997;40:544-557.
6. Geller NL: Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest 1984;2:483-491.
7. Storer BE: Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.
8. Cutler NR, Murphy MF, Nash RJ, Prior PL, DeLuna DM: Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 1990; 30: 556-561.
9. Sramek JJ, Block GA, Reines SA, Sawin SF. Barchowsky A, Cutler NR: A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1994;56:319-326.
10. Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR: The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995; 35:800-806.
11. Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR: Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995;57:503-510.
12. Sramek JJ, Vierek C, Huff FJ, Wardle TS, Hourani J, Stewart JA, Cutler NR: A "bridging" (safety/ tolerance) study of bespiridine hydrochloride in patients with Alzheimer's disease. Life Sci 1995; 57:1241-1248.
13. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR: Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58:1201-1207.
14. Cutler NR, Sramek JJ, Seifert RD, Sawin SF: The target population in phase I clinical trials of acetylcholinesterase inhibitors in dementia: the role of the "bridging study." In, Corain B, Iqbal M, Nicolini M, Winblad B, Wisniewski H, Aztta P (eds.): Alzheimer's Disease: Advances in Clinical and Basic Research. Sussex, UK: John Wiley & Sons, 1993;558-562.
15. Cutler NR, Sramek JJ: The target population in phase I clinical trials of cholinergic compounds in Alzheimer's disease: the role of the "bridging study." Alzheimer Dis Assoc Disord 1995;9:139-145.
16. Cutler NR, Sramek JJ: Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995;48:421-428.
17. Cutler NR, Sramek JJ: Drug development must be optimized in order to choose the correct strategy. In, Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds.): Research Advances in Alzheimer's Disease and Related Disorders. Sussex, UK: John Wiley & Sons, 1995;263-271.
18. Cutler NR, Sramek JJ: The bridging study: optimizing the dose for phase II/III. In, Becker R, Giacobini E (eds.): Alzheimer Disease: From Molecular Biology to Therapy. Boston: Birkhaüser, 1996; 387-391.
19. Colburn WA: Controversy V: phase I, first time in man studies. J Clin Pharmacol 1990;30:210-222.
20. Posvar EL, Sedman AJ: New drugs: first time in man. J Clin Pharmacol 1989;29:961-966.
21. Storer BE: Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.
22. Ward JF, Nardi RV: Using early drug development data to design phase III trials. Drug Inform J 1991;25:335-344.
23. Beer B, Ieni JR, Wu W, Clody D, Amorusi P, Rose J, et al: A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994; 34:335-344.
24. Smith RB, Kroboth PD, Varner PD: Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 1987;27: 971-979.
25. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J: Clinical trials and therapeutics: paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991;50(5, pt 1):573-579.
26. Storer BE: Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics 1993;49:1117-1125.
27. Collins JM, Grieshaber CK, Chabner BA: Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990;82:1321-1326.
28. Voisin EM, Ruthsatz M, Collins JM, Hoyle PC: Extrapolation of animal toxicity to humans. Regul Toxicol Pharmacol 1990;12: 107-116.
29. Porikos KP, Van Itallie TB: Diet-induced changes in serum transaminase and triglyceride levels in healthy adult men. Am J Med 1983;75:624-630.
30. Sheiner LB: A new approach to clinical drug development. In, Gender Studies in Product Development: Scientific Issues and Approaches. Rockville, MD: FDA Workshop, November 6-7, 1996.
31. Collins JM, Grieshaber CK, Chabner BA: Pharmacologically guided phase I clinical trials based on preclinical drug development. J Natl Cancer Inst 1990;82:1321-1326.
32. Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR: A "bridging" (safety tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci 1995;57:1241-1248.
33. Cutler NR, Sramek JJ: Scientific and ethical concerns in clinical trials in Alzheimer's patients. Eur J Clin Pharmacol 1995;48:421-428.
34. Cutler NR, Sramek JJ: The target population in phase I clinical trials of cholinergic compounds in Alzheimer's disease: the role of the "bridging study." Alzheimer Dis Rel Disord 1995;9:139-145.
35. Cutler NR, Sramek JJ, Murphy MF, Nash RJ: Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease. J Geriatr Psychiatry Neurol 1992;5:192-194.